PRMT1 was also responsible for promoting the Wnt and Notch pathways in ESCC, leading to increased tumour initiating cells with enhanced self-renewal capabilities and resistance to cisplatin treatment (Zhao et al., 2019). The gene discussed is PRMT1; the disease is neoplasm.